Skip to main content
Premium Trial:

Request an Annual Quote

Vin Miles, Jeff Vick, Iain Ross, Jeremy Curnock Cook

Premium
Dicerna Pharmaceuticals said this week that Vin Miles has joined its board of directors.
 
Miles is currently a venture partner at life sciences investment group Abingworth. Prior to this, he served as senior vice president of business development for RNAi drug shop Alnylam Pharmaceuticals.
 
Abingworth was an early investor in Alnylam.
 
“Miles’ deep operating experience in the biotechnology industry and familiarity with RNAi is a tremendous asset and complement to our existing capabilities,” Dicerna CEO and Co-founder Jim Jenson said in a statement.
 

 
Silence Therapeutics said this week that CEO Jeff Vick has resigned for “personal reasons.”
 
The company said its board has now appointed Iain Ross, non-executive chairman, as the full-time chairman and CEO.
 
Silence also said that Jeremy Curnock Cook, a non-executive director, has been named senior independent non-executive director.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.